CN109251224A - There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously - Google Patents
There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously Download PDFInfo
- Publication number
- CN109251224A CN109251224A CN201811320080.3A CN201811320080A CN109251224A CN 109251224 A CN109251224 A CN 109251224A CN 201811320080 A CN201811320080 A CN 201811320080A CN 109251224 A CN109251224 A CN 109251224A
- Authority
- CN
- China
- Prior art keywords
- iridium
- complex
- chemotherapy
- phototherapy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052741 iridium Inorganic materials 0.000 title claims abstract description 35
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 32
- 238000001126 phototherapy Methods 0.000 title claims abstract description 32
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- YMNKUHIVVMFOFO-UHFFFAOYSA-N anthracene-9-carbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=CC=C3)C3=CC2=C1 YMNKUHIVVMFOFO-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- KKIGUVBJOHCXSP-UHFFFAOYSA-N 4-phenylthiosemicarbazide Chemical class NNC(=S)NC1=CC=CC=C1 KKIGUVBJOHCXSP-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 6
- WQIQNKQYEUMPBM-UHFFFAOYSA-N pentamethylcyclopentadiene Chemical compound CC1C(C)=C(C)C(C)=C1C WQIQNKQYEUMPBM-UHFFFAOYSA-N 0.000 claims description 6
- 150000002503 iridium Chemical class 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 229960004756 ethanol Drugs 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- MAGSSGQAJNNDLU-UHFFFAOYSA-N s-phenylthiohydroxylamine Chemical compound NSC1=CC=CC=C1 MAGSSGQAJNNDLU-UHFFFAOYSA-N 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZCUJHHRHKBFHBG-ZLELNMGESA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 ZCUJHHRHKBFHBG-ZLELNMGESA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- JDXKTOBMLZLCSB-UHFFFAOYSA-N anilinothiourea Chemical compound NC(=S)NNC1=CC=CC=C1 JDXKTOBMLZLCSB-UHFFFAOYSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously the invention discloses a kind of, which is characterized in that its chemical structural formula are as follows:
Description
Technical field
The present invention relates to medicine technology field, it is specifically a kind of and meanwhile have the iridium of chemotherapy and phototherapy antitumor action cooperation
Object and its preparation method and application.
Background technique
Cancer is to endanger one of main disease of human health, still lacks effective treatment means so far.At present clinically
The anti-tumor drug used is mostly nucleoside medicine, and there is the similitudes of Antitumor test, has very strong toxic side effect.It is another
Aspect, certain tumor cell lines are easy to produce drug resistance to the drug of clinical application, and tumor cell line is also easy to happen variation, because
This development can overcome drug resistance or the anti-tumor drug with broad spectrum of activity to attract attention.The Antitumor test of metal complex and its
Anticancer Effect and Mechanism is different with nucleoside medicine and causes the interest of researcher.It is currently employed for clinical chemotherapy
Or tens of kinds of anti-tumor drugs of auxiliary, only there is preferable curative effect to the treatment of Partial tumors.Therefore, new gold is prepared
Metal complex anti-tumor drug can provide more better choices for the treatment of tumor disease, especially have chemotherapy and light
Treat the new antitumoral complex of synergistic effect, it has also become current research hotspot.
Summary of the invention
It is an object of the invention to solve at least the above problems, and provide the advantages of at least will be described later.
It is a still further object of the present invention to provide a kind of complex of iridium simultaneously with chemotherapy and phototherapy antitumor action,
It can be used for preparing the drug for the treatment of cancer and hypertension, while having the function of chemotherapy and phototherapy, the present invention has good life
Object activity；With conjugated system structure, molecule is more stable；Preparation method is simple, at low cost.
There is the complex of iridium of chemotherapy and phototherapy antitumor action simultaneously it is a still further object of the present invention to provide a kind of
Preparation method, using 4- phenyl -3- thiosemicarbazides and 9- anthraldehyde as raw material, by being heated to reflux, and using N atom, S atom and
Metal Ir, which is coordinated to obtain, has chemotherapy-phototherapy synergistic antitumor effect complex of iridium.
There is the complex of iridium of chemotherapy and phototherapy antitumor action simultaneously it is a still further object of the present invention to provide a kind of
Using being used to prepare anti-tumor drug.
In order to realize these purposes and other advantages according to the present invention, providing a kind of while have chemotherapy and phototherapy anti-
The complex of iridium of function of tumor, chemical structural formula are as follows:
The present invention also provides a kind of preparation methods simultaneously with the complex of iridium of chemotherapy and phototherapy antitumor action, including
Following steps:
Step 1: being heated to reflux after 4- phenyl -3- thiosemicarbazides is mixed with 9- anthraldehyde, make 4- phenyl -3- amino sulphur
The amino of urea and the carbonyl reaction of 9- anthraldehyde form C=N key, obtain 9- anthracene-N4Phenyl thiosemicarbazide.
Step 2: dichloro (pentamethylcyclopentadiene base) is closed iridium dimer and 9- anthracene-N4Phenyl thiosemicarbazide mixing,
By 9- anthracene-N4Phenyl thiosemicarbazide is coordinated to obtain with chemotherapy-phototherapy collaboration as ligand, with N atom, S atom and metal Ir
The complex of iridium of antitumor action.
Preferably, the preparation method of the complex of iridium with chemotherapy and phototherapy antitumor action while described, including
Following steps:
Step 1: sequentially adding 0.05 part of 9- anthraldehyde and 0.05 part of 4- phenyl -3- ammonia in 5 parts of dehydrated alcohol
Base thiocarbamide obtains solution I, and 0.15~0.25 pbw of glacial acetic acid is added in solution I and is heated to reflux cold filtration after 3~6h,
Obtain 9- anthracene-N4Phenyl thiosemicarbazide, wherein dehydrated alcohol, 9- anthraldehyde, 4- phenyl -3- thiosemicarbazides, glacial acetic acid ratio
Example relationship is mL:mmol:mmol:mL.
Preferably, the preparation method of the complex of iridium with chemotherapy and phototherapy antitumor action while described, including
Following steps:
Step 2: sequentially added in 3 parts of ethyl alcohol 61.8 parts dichloro (pentamethylcyclopentadiene base) close iridium dimer and
28.3 parts of 9- anthracene-N4Phenyl thiosemicarbazide and at room temperature reaction 3~5h obtain solution II, solution II is revolved
It steams to remove solvent, obtains crude product, obtain that there is chemotherapy-phototherapy synergistic antitumor effect after crude product is recrystallized
Complex of iridium, wherein ethyl alcohol, dichloro (pentamethylcyclopentadiene base) close iridium dimer, 9- anthracene-N4The ratio of phenyl thiosemicarbazide
Example relationship is mL:mg:mg.
It is a kind of while having the complex of iridium of chemotherapy and phototherapy antitumor action as the application for preparing anti-tumor drug.
Application a kind of while that there is the complex of iridium of chemotherapy and phototherapy antitumor action, the complex of iridium and auxiliary material group
Injection, tablet, pill, capsule, suspending agent or emulsion is made in conjunction.
The present invention is include at least the following beneficial effects:
Complex of the invention can be used for preparing the drug for the treatment of cancer and hypertension, can be made into injection, tablet, ball
Agent, the form use of capsule, suspending agent or emulsion.
Preparation method of the present invention is simple, has advantage at low cost, reduces material loss, meets the requirement of Green Chemistry.
Complex of the invention contains anthracene nucleus, and obtained complex has good bioactivity；There is big conjugated system, point
Son is more stable.
Complex of the invention has the function of chemotherapy and phototherapy simultaneously, more targeted for the treatment of cancer cell,
Toxic side effect is small.
Further advantage, target and feature of the invention will be partially reflected by the following instructions, and part will also be by this
The research and practice of invention and be understood by the person skilled in the art.
Specific embodiment
The present invention will be further described in detail below with reference to the embodiments, to enable those skilled in the art referring to specification
Text can be implemented accordingly.
<comparative experiments 1>
Using MTT method, vitro cytotoxicity measurement is carried out: being divided into 10% fetal calf serum, 1% dual anti-(blueness in group
Mycin-anti-streptomycin antibody) RPMI-1640 culture solution in, respectively cultivate PC3 (Human Prostate Cancer Cells), SKOV3 (people's ovary
Cancer cell) and renal epithelial cell, condition of culture is 37 DEG C, 5%CO2 and saturated humidity, change a culture solution within average 1~2 day, to
Cell passes on after covering with culture box with 0.25% trypsin digestion and to the cell in every kind of culture solution.
It takes the passage cell for being in logarithmic phase in every kind of culture solution, and is divided into 10% fetal bovine serum and 1% dual anti-with group
Culture solution be configured to concentration be 2 × 104/ mL single cell suspension.
Two pieces of sterilized 96 porocyte culture plates of every kind of single cell suspension are inoculated with, every 200 μ L of hole, in 37 DEG C, 5%
It is cultivated for 24 hours under conditions of CO2 and saturated humidity, every kind of single cell suspension is divided into 7 groups and is separately added into 7 concentration gradients
There is the complex of iridium of chemotherapy and phototherapy antitumor action simultaneously, each concentration gradient is all provided with no light group and light group.
After culture plate is placed in 37 DEG C, cultivates 4h under conditions of 5%CO2 and saturated humidity, culture solution is removed, is added new
Culture solution and a wherein plate be placed under the wavelength of 400nm irradiate 30min, this two plate is placed in training by and another plate not illumination
It supports after being cultivated for 24 hours in case, 10 μ L CCK-8 solution is added in every hole and continue to cultivate 3h, then 96 orifice plates are placed in low speed on shaking table
5~10min is shaken, finally with microplate reader (wavelength of light source is 450nm) each hole OD value of detection.
Statistical gradient experimental result calculates IC50Value, the results are shown in Table 1.
Medium effective concentration (IC of 1 complex of iridium of table to tumor cell line50)
| Cell strain | PC3 | SKOV3 | Renal epithelial cell |
| No light | 14.6±0.6 | 12.1±0.7 | > 200 |
| Illumination | 5.7±0.6 | 2.3±0.3 | > 200 |
It can be seen that while having the complex of iridium of chemotherapy and phototherapy antitumor action through external from the result of embodiment 1
Anti-tumor experiment, which shows while having the complex of iridium of chemotherapy and phototherapy antitumor action not only, has strong anti-tumor chemotherapeutic living
Property, and with strong phototherapy activity.The present invention provides new thinking to research and develop new anti-tumor drug.
<comparative experiments 2>
Substrate hippuric acid-histidine-Leucine is dissolved in the borate buffer solution of 0.1mol/L NaCl containing 0.2mol/L
(pH=8.3) in, being configured to concentration is 5.0mmol/L.Take the above-mentioned hippuric acid of 100 μ L-histidine-Leucine solution and 100 μ L
The aqueous solution that complex of iridium concentration is 0.1g/L mixes, and adds 150 μ L 0.1U/mL angiotensin converting enzyme solution and (is dissolved in
In the borate buffer solution of the 0.1mol/L substrate of NaCl containing 0.2mol/L, in 37 DEG C of reaction 60min.250 μ L concentration, which are added, is
1.0mol/L HCl terminates reaction, and ethyl acetate 1.5mL is then added and is extracted, intense oscillations 1min, at 3000r/min
It is centrifuged 5min.Ester layer 0.5mL is taken, the diaminobenzidine color developing agent of 1.0mL acetic anhydride and 2.0mL 0.5% is added, 40 DEG C aobvious
Color 30min measures its light absorption value at 459nm.
Inhibiting rate is calculated according to the following formula:
ACE inhibiting rate=[(A-S)/(A-C)] × 100%
Wherein A is the light absorption value for replacing inhibitor to be measured with water, and the light absorption value that S is measured for addition inhibitor, C is to add
The reference light absorption value of ethyl acetate, acetic anhydride and color developing agent.
Angiotensin converting enzyme (ACE) inhibiting rate (%) of 2 complex of iridium of table
| Inhibitor | ACE inhibiting rate (%) |
| Complex of iridium | 65.3 |
From calculated result it is found that having the complex of iridium of chemotherapy and phototherapy antitumor action to press down with good ACE simultaneously
Production is used.
Although the embodiments of the present invention have been disclosed as above, but its is not only in the description and the implementation listed
With it can be fully applied to various fields suitable for the present invention, for those skilled in the art, can be easily
Realize other modification, therefore without departing from the general concept defined in the claims and the equivalent scope, the present invention is simultaneously unlimited
In specific details.
Claims (6)
1. having the complex of iridium of chemotherapy and phototherapy antitumor action simultaneously, which is characterized in that its chemical structural formula are as follows:
2. the preparation method simultaneously with the complex of iridium of chemotherapy and phototherapy antitumor action as described in claim 1, special
Sign is, comprising the following steps:
Step 1: being heated to reflux after 4- phenyl -3- thiosemicarbazides is mixed with 9- anthraldehyde, make 4- phenyl -3- thiosemicarbazides
The carbonyl reaction of amino and 9- anthraldehyde forms C=N key, obtains 9- anthracene-N4Phenyl thiosemicarbazide.
Step 2: dichloro (pentamethylcyclopentadiene base) is closed iridium dimer and 9- anthracene-N4Phenyl thiosemicarbazide mixing, by 9-
Anthracene-N4Phenyl thiosemicarbazide is coordinated to obtain anti-swollen with chemotherapy-phototherapy collaboration as ligand with N atom, S atom and metal Ir
The complex of iridium of tumor effect.
3. the preparation method simultaneously with the complex of iridium of chemotherapy and phototherapy antitumor action as claimed in claim 2, special
Sign is that step 1 specifically includes: 0.05 part of 9- anthraldehyde and 0.05 part of 4- benzene are sequentially added in 5 parts of dehydrated alcohol
Base -3- thiosemicarbazides obtains solution I, and 0.15~0.25 pbw of glacial acetic acid is added in solution I and is heated to reflux cold after 3~6h
But it filters, obtains 9- anthracene-N4Phenyl thiosemicarbazide, wherein dehydrated alcohol, 9- anthraldehyde, 4- phenyl -3- thiosemicarbazides, ice vinegar
The proportionate relationship of acid is mL:mmol:mmol:mL.
4. the preparation method simultaneously with the complex of iridium of chemotherapy and phototherapy antitumor action as claimed in claim 2, special
Sign is that step 2 specifically includes: sequentially adding 61.8 parts of dichloro (pentamethylcyclopentadiene base) in 3 parts of ethyl alcohol and closes iridium two
Aggressiveness and 28.3 parts of 9- anthracene-N4Phenyl thiosemicarbazide and at room temperature reaction 3~5h obtain solution II, by solution II
It is rotated to remove solvent, obtains crude product, obtained after crude product is recrystallized with chemotherapy-phototherapy synergistic antitumor
The complex of iridium of effect, wherein ethyl alcohol, dichloro (pentamethylcyclopentadiene base) close iridium dimer, 9- anthracene-N4Phenyl amino sulphur
The proportionate relationship of urea is mL:mg:mg.
5. as described in claim 1 have the complex of iridium of chemotherapy and phototherapy antitumor action antitumor as preparing simultaneously
The application of drug.
6. the application simultaneously with the complex of iridium of chemotherapy and phototherapy antitumor action as described in claim 1, feature exist
In injection, tablet, pill, capsule, suspending agent or emulsion is made in the complex of iridium and auxiliary material combination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811320080.3A CN109251224B (en) | 2018-11-07 | 2018-11-07 | Iridium complex with chemotherapeutic and phototherapy antitumor effects simultaneously and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811320080.3A CN109251224B (en) | 2018-11-07 | 2018-11-07 | Iridium complex with chemotherapeutic and phototherapy antitumor effects simultaneously and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109251224A true CN109251224A (en) | 2019-01-22 |
| CN109251224B CN109251224B (en) | 2020-08-14 |
Family
ID=65044815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811320080.3A Active CN109251224B (en) | 2018-11-07 | 2018-11-07 | Iridium complex with chemotherapeutic and phototherapy antitumor effects simultaneously and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109251224B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217732A (en) * | 2020-02-24 | 2020-06-02 | 曲阜师范大学 | Lysosome-targeted fluorescent metal iridium dimer and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288727A (en) * | 2015-11-17 | 2016-02-03 | 广西中医药大学 | Method for preparing antibacterial and anti-cancer titanium dioxide nano-tubes by using rhodium coordination compound |
| CN105327391A (en) * | 2015-11-17 | 2016-02-17 | 广西中医药大学 | Method for preparing anti-bacterial and anti-cancer titanium dioxide nanotube from iridium complex |
| CN105396174A (en) * | 2015-11-20 | 2016-03-16 | 广西中医药大学 | Method for preparing titanium dioxide nanotube with antibacterial and anti-cancer properties |
| CN105457088A (en) * | 2015-11-20 | 2016-04-06 | 广西中医药大学 | Method for preparing titanium metal with antimicrobial and anticancer performance |
-
2018
- 2018-11-07 CN CN201811320080.3A patent/CN109251224B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288727A (en) * | 2015-11-17 | 2016-02-03 | 广西中医药大学 | Method for preparing antibacterial and anti-cancer titanium dioxide nano-tubes by using rhodium coordination compound |
| CN105327391A (en) * | 2015-11-17 | 2016-02-17 | 广西中医药大学 | Method for preparing anti-bacterial and anti-cancer titanium dioxide nanotube from iridium complex |
| CN105396174A (en) * | 2015-11-20 | 2016-03-16 | 广西中医药大学 | Method for preparing titanium dioxide nanotube with antibacterial and anti-cancer properties |
| CN105457088A (en) * | 2015-11-20 | 2016-04-06 | 广西中医药大学 | Method for preparing titanium metal with antimicrobial and anticancer performance |
Non-Patent Citations (2)
| Title |
|---|
| FLOYD A. BECKFORD等: "Novel microwave synthesis of half-sandwich [(η6-C6H6)Ru] complexes and an evaluation of the biological activity and biochemical reactivity", 《APPL. ORGANOMETAL. CHEM.》 * |
| NANDHAGOPAL RAJA等: "Biological activities of pyrenyl-derived thiosemicarbazone half-sandwich complexes", 《JOURNAL OF ORGANOMETALLIC CHEMISTRY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217732A (en) * | 2020-02-24 | 2020-06-02 | 曲阜师范大学 | Lysosome-targeted fluorescent metal iridium dimer and preparation method and application thereof |
| CN111217732B (en) * | 2020-02-24 | 2021-09-24 | 曲阜师范大学 | Lysosome-targeted fluorescent metal iridium dimer and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109251224B (en) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107556361A (en) | Driffractive ring lupinane derivative and its anticancer usage | |
| CN102218069B (en) | Applicationof A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments | |
| US8853194B2 (en) | Sterol derivatives and their synthesis and use | |
| CN107417580A (en) | One kind has the gossypol L arginine Schiff bases compounds and its synthetic method of antitumor activity | |
| CN105985358B (en) | Liu Yazi total alkaloid extract and its preparation method and application | |
| CN104250282A (en) | Diosgenin amino acid derivative and application thereof to antitumor drug | |
| CN104447322B (en) | Single Demethoxycurcumin soluble derivative and its production and use | |
| CN109251224A (en) | There is chemotherapy and the complex of iridium of phototherapy antitumor action and its preparation method and application simultaneously | |
| CN107141284B (en) | Coptisine analog derivative, preparation method, pharmaceutical composition and anticancer usage | |
| CN102688489B (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
| CN108553455B (en) | Application of trialdehyde phloroglucinol thiosemicarbazone heterozygote compound in antitumor drugs | |
| CN109265487A (en) | Complex of iridium and its preparation method and application with chemotherapy and phototherapy synergistic antitumor effect | |
| CN106674323B (en) | Pentacyclic triterpenoid and application thereof with ACC1 protein regulation effect | |
| CN111499605B (en) | Isopentene chromone compound and preparation method and application thereof | |
| CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
| CN103351383B (en) | 5-fluorouracil nitroxyl-free-radical anti-tumor drug | |
| CN101289453B (en) | Ellagic acid compounds preparation method | |
| CN103463643A (en) | Preparation and application of human serum albumin-ruthenium inorganic medicine compound | |
| CN104892707A (en) | Compound CLCN based on oriented synthesis and application of CLCN to anti-liver cancer drugs | |
| CN105481944B (en) | A kind of two peptide copper complex of benzimidizole derivatives and its preparation method and application | |
| CN109528627A (en) | A kind of Ru-BSA hydrogel and the preparation method and application thereof | |
| CN109438525B (en) | Compound with chemotherapy and phototherapy antitumor effects and preparation method and application thereof | |
| CN103880793B (en) | Containing furan imine compound and its production and use | |
| CN109232662B (en) | Compound with anti-tumor effect and preparation method and application thereof | |
| CN103304556B (en) | Schiff bases compounds containing chromene, Preparation Method And The Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |